SEAK THERAPEUTICS, LLC

Address: 3 N DUNLAP ST STE C303 MEMPHIS, TN 38103-2802
County: SHELBY
Country: UNITED STATES
UEI: HBTSD5J8NL84

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2025 ( Subtotal = $399,981 )

2025

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R41CA310186

Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis

000

NIH

9/18/2025

$399,981

2025

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R41CA310186

Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis

001

NIH

9/19/2025

2025

2023

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R41NS135658

Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

000

NIH

3/31/2025

Issue Date FY: 2024 ( Subtotal = $0 )

2024

2020

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R43CA257324

Feasibility study of developing SEAK-114 for the treatment of pediatric cancers

000

NIH

10/13/2023

Issue Date FY: 2023 ( Subtotal = $429,932 )

2023

SEAK THERAPEUTICS LLC

3 N DUNLAP ST

MEMPHIS

38103-2802

SHELBY

USA

R41NS135658

Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

000

NIH

9/20/2023

$429,932

Issue Date FY: 2022 ( Subtotal = $0 )

2022

2020

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R43CA257324

Feasibility study of developing SEAK-114 for the treatment of pediatric cancers

000

NIH

8/30/2022

Issue Date FY: 2021 ( Subtotal = $0 )

2021

2020

SEAK THERAPEUTICS, LLC

20 DUDLEY ST STE 900

MEMPHIS

38103-4904

SHELBY

USA

R43CA257324

Feasibility study of developing SEAK-114 for the treatment of pediatric cancers

000

NIH

1/7/2021

2021

2019

SEAK THERAPEUTICS, LLC

3 N DUNLAP ST STE C303

MEMPHIS

38103-2802

SHELBY

USA

R43CA246788

Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers

000

NIH

3/19/2021

Issue Date FY: 2020 ( Subtotal = $454,964 )

2020

SEAK THERAPEUTICS, LLC

20 DUDLEY ST STE 900

MEMPHIS

38103-4904

SHELBY

USA

R43CA257324

Feasibility study of developing SEAK-114 for the treatment of pediatric cancers

000

NIH

9/17/2020

$399,964

2020

SEAK THERAPEUTICS, LLC

20 DUDLEY ST STE 900

MEMPHIS

38103-4904

SHELBY

USA

R43CA246788

Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers

000

NIH

8/12/2020

$55,000

Issue Date FY: 2019 ( Subtotal = $299,823 )

2019

SEAK THERAPEUTICS, LLC

20 DUDLEY ST STE 900

MEMPHIS

38103-4904

SHELBY

USA

R43CA246788

Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers

000

NIH

9/12/2019

$299,823

All Categories

About

Search

Reports

Data Submission

Recipient Information

SEAK THERAPEUTICS, LLC

Address: 3 N DUNLAP ST STE C303 MEMPHIS, TN 38103-2802

County: SHELBY

Country: UNITED STATES

UEI: HBTSD5J8NL84

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer